Blog Business Entertainment Environment Health Latest News News Analysis Opinion Science Sports Technology Videos World
John Green Speaks Out for Global Change with TB Medication

In recent days, beloved American writer, John Green has taken to social media to expose the injustice perpetuated by recent patenting decisions by medical and pharmaceutical giant Johnson & Johnson. In the post, Green called out J&J for renewing a twenty-year patent that was set to expire this month. The extended patent will monopolize the treatment and deny drug access to thousands according to Green.


J&J’s patent is on the drug bedaquiline which was approved in 2012 by the FDA to treat drug-resistant TB. However, since the initial creation of the drug in 2003, J&J has maintained a patent on the formular, preventing any generic versions to be produced.


In 2007, the formula was slightly altered with an additive and a new patent was created. Instead of honoring the original patent that would expire in 2023, J&J opted to hold out until the expiry date of the 2007 patent, preventing generic versions of the drug for another four years. This motion was denied by the United States government, however, other countries allowed it and still don’t have access to more affordable alternatives. In his post, Green explains that in the 4 years the patent is extended, six million people who should have access to a generic TB medication will not, and that most of those people will die.


It is estimated that a generic version of the medication would cost an estimated 60% less than the J&J branded one.


After John Green’s initial post, the news took off across social media platforms with many activists and influencers calling out J&J for violating their brand credo and denying millions of accessible medications.


Within days, J&J adjusted its trajectory and took a step toward inclusivity and accessibility as they partnered with the Stop TB Partnership. On Thursday, July 13th, J&J granted them access to tender, procure and supply the generic form of bedaquiline to low to middle-income countries.

Share This Post On

Tags: #tb #j&j #johngreen #johnson&johnson


Leave a comment

You need to login to leave a comment. Log-in is a Global Media House Initiative by Socialnetic Infotainment Private Limited.

TheSocialTalks was founded in 2020 as an alternative to mainstream media which is fraught with misinformation, disinformation and propaganda. We have a strong dedication to publishing authentic news that abides by the principles and ethics of journalism. We are an organisation driven by a passion for truth and justice in society.

Our team of journalists and editors from all over the world work relentlessly to deliver real stories affecting our society. To keep our operations running, We need sponsors and subscribers to our news portal. Kindly sponsor or subscribe to make it possible for us to give free access to our portal and it will help writers and our cause. It will go a long way in running our operations and publishing real news and stories about issues affecting us.

Your contributions help us to expand our organisation, making our news accessible to more everyone and deepening our impact on the media.

Support fearless and fair journalism today.